Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Budesonide/formoterol combination in COPD: a US perspective

Authors Amir Sharafkhaneh, Amarbir S Mattewal, Vinu M Abraham, et al

Published 4 October 2010 Volume 2010:5 Pages 357—366

DOI https://dx.doi.org/10.2147/COPD.S4215

Review by Single-blind

Peer reviewer comments 3

Amir Sharafkhaneh1,2, Amarbir S Mattewal1, Vinu M Abraham1, Goutham Dronavalli1, Nicola A Hanania1
1Section of Pulmonary, Critical Care Medicine and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA; 2Section of Pulmonary, Critical Care Medicine and Sleep Medicine, Medical Care Line, Michael E DeBakey VA Medical Center, Houston, Texas, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease of the lung caused primarily by exposure to cigarette smoke. Clinically, it presents with progressive cough, sputum production, dyspnea, reduced exercise capacity, and diminished quality of life. Physiologically, it is characterized by the presence of partially reversible expiratory airflow limitation and hyperinflation. Pathologically, COPD is a multicomponent disease characterized by bronchial submucosal mucous gland hypertrophy, bronchiolar mucosal hyperplasia, increased luminal inflammatory mucus, airway wall inflammation and scarring, and alveolar wall damage and destruction. Management of COPD involves both pharmacological and nonpharmacological approaches. Bronchodilators and inhaled corticosteroids are recommended medications for management of COPD especially in more severe disease. Combination therapies containing these medications are now available for the chronic management of stable COPD. The US Food and Drug Administration, recently, approved the combination of budesonide/formoterol (160/4.5 µg; Symbicort™, AstraZeneca, Sweden) delivered via a pressurized meter dose inhaler for maintenance management of stable COPD. The combination also is delivered via dry powder inhaler (Symbicort™ and Turbuhaler™, AstraZeneca, Sweden) but is not approved for use in the United States. In this review, we evaluate available data of the efficacy and safety of this combination in patients with COPD.

Keywords: inhaled steroid, bronchodilator, ß2-agonist, lung function, quality of life, COPD exacerbations

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Exenatide improves glucocorticoid-induced glucose intolerance in mice

Ruiying Zhao, Enrique Fuentes-Mattei, Guermarie Velazquez-Torres, et al

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4:61-65

Published Date: 26 January 2011

Improving adherence with inhaler therapy in COPD

Suzanne C Lareau, Barbara P Yawn

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:401-406

Published Date: 24 November 2010

Cardiac injury in patients with COPD presenting with dyspnea: a pilot study

Esosa Odigie-Okon, Bryan Jordan, Sylvester Dijeh, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:395-399

Published Date: 9 November 2010

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease

Heike Rau-Berger, Harald Mitfessel, Thomas Glaab

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:367-373

Published Date: 10 October 2010

Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD

Yudong Wen, David W Reid, Dongcheng Zhang, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:327-334

Published Date: 28 September 2010

Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters

L Pekka Malmberg, Paula Rytilä, Pertti Happonen, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:257-262

Published Date: 4 August 2010

Nebulized formoterol: a review of clinical efficacy and safety in COPD

Nicholas J Gross, James F Donohue

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:223-232

Published Date: 28 June 2010

A day at a time: caregiving on the edge in advanced COPD

A Catherine Simpson, Joanne Young, Margaret Donahue, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:141-151

Published Date: 10 May 2010